NCT05529030 is a NA clinical trial of Salience of Omicron variant in Vaccination Refusal, sponsored by Geisinger Clinic.

Who is sponsoring NCT05529030?

NCT05529030 is sponsored by Geisinger Clinic.

What drugs are being tested in NCT05529030?

Interventions in NCT05529030: Salience of Omicron variant, Self-protection message, Other-protection message.

What condition does NCT05529030 study?

NCT05529030 studies Vaccination Refusal.

Is NCT05529030 still recruiting?

NCT05529030 is currently completed. Last updated 30 September 2022.

Last reviewed 2022-09-30 · How we verify

NCT05529030

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

COVID-19 Booster Readiness Survey

Completed NA Last updated 30 September 2022

What this trial tests

NA trial testing Salience of Omicron variant in Vaccination Refusal in 12,036 participants. Completed in 15 September 2022.

Timeline

1 September 2022

Primary endpoint
15 September 2022

15 September 2022

Quick facts

Lead sponsor	Geisinger Clinic
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	prevention
Enrollment	12,036
Start date	1 September 2022
Primary completion	15 September 2022
Estimated completion	15 September 2022
Sites	1 location across United States

Drugs / interventions tested

Salience of Omicron variant
Self-protection message
Other-protection message

Conditions studied

Vaccination Refusal — all drugs for Vaccination Refusal →

Sponsor

Geisinger Clinic

Who can join

18 and older, any sex, with Vaccination Refusal. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this administrative survey is to inform health system logistics by assessing the attitudes towards towards the bivalent COVID-19 boosters held by healthcare workers (HCWs) at a large, rural health system. It will also test, prospectively, the effect on interest in the bivalent COVID-19 booster of different framing approaches in a survey question sent to employees of a large, rural health system.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Vaccination Refusal

Currently open trials in the same condition.

NCT04779827 — Improving Health Equity for COVID-19 Vaccination for At-risk Populations Using Online Social Networks · NA · active not recruiting

Other Geisinger Clinic trials

Trials by the same sponsor.

NCT07197801 — Evaluation of a Peer Recovery Support Program Adapted to Target Retention in Clinic-based Medication for Opioid Use Diso · NA · recruiting
NCT06936709 — Perioperative Colchicine for TKA · Phase 4 · not yet recruiting
NCT07042477 — Integrated Telemedicine Program Evaluation · NA · recruiting
NCT07028398 — CMSL Ambulatory Sensitive Condition Nudge Study 2 · NA · recruiting
NCT06696066 — PEERS Pilot: Peer Recovery Support Program to Support Engagement in Medication for Opioid Use Disorder · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05529030 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Geisinger Clinic
Last refreshed: 30 September 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05529030.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing